Welcome to our dedicated page for Basel Medical Group SEC filings (Ticker: BMGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Basel Medical Group Ltd (BMGL) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Basel Medical files reports under the Securities Exchange Act of 1934, including Form 6-K current reports and an annual report on Form 20-F, which together outline its healthcare operations, governance, auditor relationships and capital markets activity.
Through these filings, readers can review information about Basel Medical’s role as a Singapore-based provider of orthopedic and trauma services, sports medicine and surgery, orthopedic procedures and neurosurgical treatments, as well as its broader activities in general practice, health screening, mental health, women’s health and diagnostic imaging through subsidiaries such as Bethesda Medical Pte. Ltd. Filings also document the company’s relationships with corporate clients in sectors like construction, marine and oil & gas, and its expansion strategy in Singapore and Southeast Asia.
Recent Form 6-K reports have covered topics such as the appointment of NLA DFK Assurance PAC as independent registered public accounting firm and the dismissal of Onestop Assurance PAC, leadership changes including executive appointments and resignations, and the use of specific 6-K submissions to satisfy Form 20-F requirements related to auditor changes. Another key filing area involves Basel Medical’s capital markets transactions, including its initial public offering, exercise of an overallotment option and intended uses of offering proceeds for mergers and acquisitions, clinic expansion, auxiliary services and technology upgrades.
Regulatory compliance and listing status are also reflected in the company’s disclosures. Basel Medical has reported a delinquency notification from Nasdaq concerning an incomplete Form 20-F that lacked an auditor’s opinion, and has outlined the process and timeline for submitting a plan to regain compliance. On Stock Titan, these filings are complemented by AI-powered summaries that explain the significance of each document, helping users interpret auditor changes, listing notifications, capital-raising plans and other technical disclosures without reading every page in full.
Investors can use this page to monitor Basel Medical’s Form 20-F annual report, Form 6-K current reports and related exhibits, and to understand how developments in its healthcare operations, acquisitions, healthcare products contracts and financial strategies are reflected in official SEC filings.
Basel Medical Group Ltd Chief Financial Officer Lu Jianing JN has filed an initial insider ownership report on Form 3. The filing lists no buy or sell transactions, and shows no derivative securities positions reported for this insider at this time.
Basel Medical Group Ltd director Tony Chen filed an initial Form 3 statement of beneficial ownership. The filing lists him as a director of BMGL but shows no reported transactions or derivative positions in this data, indicating only an initial disclosure of insider status.
Basel Medical Group Ltd Chief Executive Officer Chhoa Darren Yen Feng has filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing excerpt shows no reported transactions and no listed derivative positions for the reporting person.
Basel Medical Group Ltd director and Chief Commercial Officer Tan Boon Chye (Darren) filed an initial ownership report showing indirect holdings in the company’s ordinary shares. A Singapore variable capital company, Rainforest Capital VCC, holds 10,205,229 ordinary shares on behalf of four subfunds.
One subfund, Basel Medical Fund, lists Tan Boon Chye as an ultimate beneficial owner, so he may be deemed to beneficially own a portion of these shares. He expressly disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest, and the filing does not report any new purchase or sale.
Basel Medical Group Ltd director Fung Keng Leong filed an initial ownership report showing indirect holdings of the company’s ordinary shares. The filing states that Rainforest Capital VCC, a Singapore variable capital company, holds 10,205,229 ordinary shares of Basel Medical Group Ltd on behalf of four subfunds.
The footnote explains that Fung is an ultimate beneficial owner of the Basel Medical Fund subfund and may be deemed to beneficially own the shares that Rainforest Capital VCC holds for that subfund. He disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest in them.
Basel Medical Group Ltd reported a change in its board of directors. The company appointed its Chief Commercial Officer, Mr. Tan Boon Chye (Darren), as a director on the board. He replaces Ms. Jianing Lu, who resigned as a director on the same day but continues to serve as the company’s Chief Financial Officer.
Basel Medical Group Ltd reports that Nasdaq has confirmed the company is now in full compliance with the exchange’s periodic filing requirement under Listing Rule 5250(c)(1). This follows Basel Medical’s amended Form 20-F for fiscal year 2025, filed on March 13, 2026, and means the prior filing-related deficiency has been resolved.
The company continues operating as a Singapore-based medical services group focused on orthopedic, neurosurgical and general healthcare, serving corporate and individual patients across multiple clinic locations in Singapore.
Basel Medical Group Ltd has filed Amendment No. 1 to its Form 20-F for the year ended June 30, 2025, to amend and restate key narrative sections and its audited consolidated financial statements for FY2024 and FY2025, and to file a new audit report from NLA DFK Assurance PAC.
The company updates risk factors, business overview, organizational structure, related party transactions and principal accountant fee disclosures, and refiles its list of subsidiaries as of March 13, 2026. Basel Medical, a BVI-incorporated orthopedic and sports medicine group operating in Singapore, had 18,785,750 ordinary shares outstanding as of June 30, 2025, and highlights extensive business, regulatory, data security and governance risks tied to its public listing, foreign private issuer and controlled company status.
Basel Medical Group Ltd director Paul D. Freudenthaler filed an initial ownership report on Form 3. This filing identifies him as a director of the company but does not list any specific share transactions or changes in ownership. It serves as a baseline disclosure of his status as an insider.
Basel Medical Group Ltd has received a delinquency notification from Nasdaq because its shares’ closing bid price has been below $1 for the last 30 consecutive business days, violating Nasdaq’s minimum bid price rule for listed securities. The company has a 180 calendar day compliance period, until July 21, 2026, to regain compliance; if its closing bid price is at least $1 for a minimum of ten consecutive business days during this period, Nasdaq will confirm compliance. Basel Medical may also choose to implement a reverse stock split, which must be completed no later than ten business days before the July 21, 2026 deadline to help restore the share price.
If compliance is not regained in this initial period, the company may qualify for an additional 180 calendar days if it meets all other initial listing standards for The Nasdaq Capital Market, except for the bid price requirement, and notifies Nasdaq of its intention to cure the deficiency, potentially via a reverse stock split. If these conditions are not met, Nasdaq may move to delist the shares. Basel Medical states it is working with professional advisers on a rectification plan, and trading of its shares on Nasdaq is currently not affected by the non-compliance.